Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.

Trial Details

NCT ID
NCT05201404
Phase
PHASE3
Sponsor
Can-Fite BioPharma
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Namodenoson
  • Placebo
Locations (sample)
  • Dallas, Texas, United States|32.78306,-96.80667
  • Banja Luka, Bosnia and Herzegovina|44.77879,17.20629
  • Mostar, Bosnia and Herzegovina|43.34333,17.80806
  • Sarajevo, Bosnia and Herzegovina|43.84864,18.35644
  • Burgas, Bulgaria|42.50651,27.46886

Key Eligibility Criteria

  • Males and females at least 18 years of age.
  • Diagnosis of HCC:
  • For patients without cirrhosis at the time of diagnosis, histologic confirmation is required (archival tissue is acceptable).
  • For patients with underlying cirrhosis at the time of diagnosis, diagnosis of HCC established according to the American Association for the Study o…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →